Research purposes:
1. To investigate the efficacy and safety of SCCCG-BL/DLBCL-2017 in children with BL and DLBCL.
2. To investigate the effect of rituximab combined with chemotherapy on the survival rate of children with high-risk BL/DLBCL.
3. To investigate the effect of rituximab on immune function in children with high-risk BL/DLBCL.
4. To explore the correlation between MRD detection and the efficacy and survival of children with BL/DLBCL.
5. To explore the role of PET/CT in evaluating residual lesions in children after BL/DLBCL treatment.
Age
1–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age \< 18 years old
2. Pathologically confirmed Burkitt lymphoma or diffuse large B-cell lymphoma
3. Newly diagnosed patients
4. Informed consent of guardian of children patients
You may not be if
1. Pathological components with follicular lymphoma
2. Immunodeficiency Second neoplasm
Clareo Health | Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL
